Last Updated on July 4, 2021 by The Health Master
Zydus Cadila has received final approval from US Food and Drug Administration (USFDA) to market emtricitabine and tenofovir disoproxil fumarate tablets, 100 mg/150 mg, 133 mg/200 mg and 167 mg/250 mg.
The drug is used with other HIV medications to help control HIV infection. It helps to decrease the amount of HIV in one’s body so that the immune system can work better.
The drug will be manufactured at the group’s formulation manufacturing facility at SEZ, Ahmedabad.
The group now has 319 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.
Alembic gets USFDA nod for Nitrofurantoin Capsules USP
Axio Biosolution gets USFDA nod for Patch for bleeding control
Glenmark gets USFDA nod for generic Lung cancer drug
USFDA okays Tocilizumab for treatment of Covid-19
Zydus Cadila gets tentative nod from USFDA for Pemetrexed for Injection
Cipla gets USFDA nod for Inhalation product
Busting Myths of Vaccination
172 Drug Inspectors appointed as Medical Device Officer
These 5 Pharma giants join hands to test oral C-19 drug
DCGI denied approval for final trial of Sputnik Light to Dr…
NPPA fixes retail prices of 3 formulations
DCGI allows Cipla to import Moderna vaccine in India
For informative videos by The Health Master, click on the below YouTube icon: